IDEAYA Biosciences Inc. (NASDAQ: IDYA) announced that data from its Phase 2 clinical trial of neoadjuvant darovasertib in primary uveal ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE